Assessment of health-related quality of life (HRQoL) in triple-class-exposed patients with relapsed or refractory multiple myeloma (RRMM) treated with linvoseltamab in the LINKER-MM1 trial

被引：0
|
作者：
Hoffman, James E.
Bumma, Naresh
Richter, Joshua Ryan
Dhodapkar, Madhav V.
Lee, Hans C.
Suvannasankha, Attaya
Zonder, Jeffrey A.
Maly, Joseph J.
Shah, Mansi R.
Baz, Rachid C.
DeVeaux, Michelle
Ivanescu, Cristina
Rodriguez-Lorenc, Karen
Kroog, Glenn Scott
Houvras, Yariv J.
Inocencio, Timothy J.
Chi, Lei
Harnett, James
Ma, Qiufei
Jagannath, Sundar
机构：
[1] Univ Miami Hlth Syst, Miami, FL USA
[2] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH USA
[3] Icahn Sch Med Mt Sinai, New York, NY USA
[4] Emory Univ, Sch Med, Atlanta, GA USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[6] Indiana Univ, Simon Canc Ctr, Indianapolis, IN USA
[7] Indiana Univ, Roudebush VAMC, Indianapolis, IN USA
[8] Karmanos Canc Inst, Detroit, MI USA
[9] Norton Canc Inst, Louisville, KY USA
[10] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[11] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[12] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e23185
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Variation in Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients by Insurance Coverage
    Pashos, Chris L.
    Durie, Brian G. M.
    Rifkin, Robert
    Terebelo, Howard
    Gasparetto, Cristina
    Mehta, Jayesh
    Toomey, Kathleen
    Abonour, Rafat
    Fonseca, Rafael
    Narang, Mohit
    Shah, Jatin J.
    Swem, Arlene S.
    Sullivan, Kristen A.
    Street, Thomas K.
    Khan, Zeba M.
    BLOOD, 2011, 118 (21) : 1361 - 1362
  • [42] A health-related quality-of-life (HRQoL) analysis of pomalidomide plus low-dose dexamethasone plus daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment.
    Reece, Donna Ellen
    Bahlis, Nizar J.
    Samaras, Christy Joy
    Sebag, Michael
    Berdeja, Jesus G.
    Ganguly, Siddartha
    Matous, Jeffrey
    Song, Kevin W.
    Seet, Christopher
    Talamo, Giampaolo
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald
    Anz, Bertrand Marquess
    Fonseca, Gustavo A.
    Agarwal, Amit
    Chung, Weiyuan
    Zafar, Faiza
    Siegel, David Samuel DiCapua
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] Quality of life (QOL) assessment in patients with relapsed/refractory multiple myeloma (MM) treated with thalidomide (T) plus celecoxib (Cxb).
    Mileshkin, LR
    Roberts, A
    Ganju, V
    Underhill, C
    Catalano, J
    Bell, R
    Lillie, K
    Milner, AD
    Zeldis, JB
    Prince, HM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 786S - 786S
  • [44] Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma
    Einsele, Hermann
    Moreau, Philippe
    Bahlis, Nizar
    Bhutani, Manisha
    Vincent, Laure
    Karlin, Lionel
    Perrot, Aurore
    Goldschmidt, Hartmut
    van de Donk, Niels W. C. J.
    Ocio, Enrique M.
    Martinez-Lopez, Joaquin
    Rodriguez-Otero, Paula
    Dytfeld, Dominik
    Diels, Joris
    Strulev, Vadim
    Haddad, Imene
    Renaud, Thomas
    Ammann, Eric
    Cabrieto, Jedelyn
    Perualila, Nolen
    Gan, Ryan
    Zhang, Youyi
    Parekh, Trilok
    Albrecht, Claire
    Weisel, Katja
    Mateos, Maria-Victoria
    ADVANCES IN THERAPY, 2024, 41 (04) : 1576 - 1593
  • [45] Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3, a Phase III Randomized Controlled Trial (RCT)
    Giralt, Sergio
    Ailawadhi, Sikander
    Arnulf, Bertrand
    Patel, Krina
    Cavo, Michele
    Nooka, Ajay K.
    Manier, Salomon
    Callander, Natalie
    Costa, Luciano J.
    Vij, Ravi
    Bahlis, Nizar J.
    Moreau, Philippe
    Solomon, Scott R.
    Delforge, Michel
    Berdeja, Jesus
    Truppel-Hartmann, Anna
    Yang, Zhihong
    Favre-Kontula, Linda
    Wu, Fan
    Piasecki, Julia
    Cook, Mark
    Rodriguez-Otero, Paula
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S527 - S528
  • [46] Health-related quality of life (HRQL) among real-world Ide-Cel-eligible patients (pts) with relapsed/refractory Multiple Myeloma (RRMM): results from the Connect® MM registry
    Wagner, Lynne
    Abonour, Rafat
    Ailawadhi, Sikander
    Durie, Brian G. M.
    Gasparetto, Cristina J.
    Hardin, James W.
    Lee, Hans
    Narang, Mohit
    Rifkin, Robert
    Terebelo, Howard
    Toomey, Kathleen
    Joshi, Prashant
    Agarwal, Amit
    Braverman, Julia
    Dhanda, Devender S.
    He, Mia
    Jagannath, Sundar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S109 - S109
  • [47] Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone +/- subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    Boccadoro, Mario
    Delimpasi, Sosana
    Beksac, Meral
    Katodritou, Eirini
    Moreau, Philippe
    Pompa, Alessandra
    Symeonidis, Argiris
    Bila, Jelena
    Oriol, Albert
    Mateos, Maria-Victoria
    Einsele, Hermann
    Orfanidis, Ioannis
    Gries, Katharine S.
    Fastenau, John
    Liu, Kevin
    He, Jianming
    Kampfenkel, Tobias
    Qiu, Yanping
    Amin, Himal
    Carson, Robin
    Sonneveld, Pieter
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (04) : 481 - 490
  • [48] Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-Related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma ( RRMM): Final Data from the Phase 2 ELOQUENT-3 Trial
    Weisel, Katja
    Dimopoulos, Meletios A.
    San-Miguel, Jesus
    Paner, Agne
    Engelhardt, Monika
    Taylor, Fiona
    Lord-Bessen, Jennifer
    Yao, David
    Yip, Christine
    Greenwood, Mike
    Tang, Jackson
    Cavo, Michele
    BLOOD, 2021, 138
  • [49] Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) Improves Health-Related Quality Of Life (HRQoL) Vs High-Dose Dexamethasone (HiDEX) In Relapsed Refractory Multiple Myeloma (RRMM) Patients Enrolled In MM-003 Phase 3 Randomized Trial
    Song, Kevin W.
    Dimopoulos, Meletios A.
    Weisel, Katja
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Moreau, Philippe
    Banos, Anne
    Oriol, Albert
    Spencer, Andrew
    Knop, Stefan
    Renner, Christoph
    Bahlis, Nizar J.
    Amatya, Ramesh
    Yu, Xin
    Monzini, Mara Silvia
    Sternas, Lars
    Zaki, Mohamed H.
    Jacques, Christian J.
    San Miguel, Jesus F.
    BLOOD, 2013, 122 (21)
  • [50] Idecabtagene Vicleucel (ide-cel) in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): the 5-year Follow-Up Analysis from KarMMa
    Anderson, Larry
    San-Miguel, Jesus
    Martin, Thomas
    Jagannath, Sundar
    Berdeja, Jesus G.
    Lonial, Sagar
    Raje, Noopur
    Lin, Yi
    Siegel, David
    Oriol, Albert
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Ishida, Tadao
    Truppel-Hartmann, Anna
    Chaudhry, Maria
    Masciulli, Arianna
    Peeramsetti, Sharavi
    Wu, Fan
    Shamsuzzaman, Md
    Thompson, Ethan
    Martin, Nathan
    Campbell, Timothy
    Munshi, Nikhil
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S81 - S82
12345